Iloperidone: New FDA Approval for Bipolar 1 Disorder
In a significant stride forward in mental health treatment, the Food and Drug Administration (FDA) has recently approved Iloperidone for the management of bipolar disorder.
This milestone marks a new chapter in the treatment landscape for individuals grappling with this complex condition.
Watch our YouTube video, where Dr. Harvinder Singh has summarized this medication in the following sections:
- Indication
- How to Dose?
- When to Adjust Dose?
- Drug Interactions
- Restarting after Discontinuation
- Use in Specific Population
- Common Adverse Reactions
- Warnings & Precautions
- Clinical Studies
WATCH DISCUSSION:
Here is one slide from the above presentation:
FOR ACADEMY MEMBERS:
BIPOLAR AND RELATED DISORDER
LECTURE SERIES
academy
JOIN EMAIL NEWSLETTER (FREE):
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
